Seeing Is Believing
Currently out of the existing stock ratings of Geoffrey Porges, 135 are a BUY (67.5%), 64 are a HOLD (32%), 1 are a SELL (0.5%).
Analyst Geoffrey Porges, currently employed carries an average stock price target met ratio of 69.61% that have a potential upside of 28.15% achieved within 374 days. Previously, Geoffrey Porges worked at LEERINK.
Geoffrey Porges’s has documented 414 price targets and ratings displayed on 25 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on RCUS, Arcus Biosciences at 04-Aug-2022.
Analyst best performing recommendations are on DOVA (DOVA PHARMACEUTICALS).
The best stock recommendation documented was for VRTX (VERTEX PHARMACEUTICALS) at 4/30/2020. The price target of $263 was fulfilled within 4 days with a profit of $11.8 (4.7%) receiving and performance score of 11.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$206
$23.2 (12.69%)
$153
11 days ago
(22-Nov-2024)
13/14 (92.86%)
$27.92 (15.68%)
293
Buy
$205
$22.2 (12.14%)
18 days ago
(15-Nov-2024)
2/3 (66.67%)
$39.27 (23.70%)
507
Buy
$200
$17.2 (9.41%)
$190
20 days ago
(13-Nov-2024)
12/13 (92.31%)
$28.57 (16.67%)
490
Buy
$224
$41.2 (22.54%)
$231
21 days ago
(12-Nov-2024)
12/15 (80%)
$48.86 (27.90%)
488
Buy
$215
$32.2 (17.61%)
$226
21 days ago
(12-Nov-2024)
8/10 (80%)
$39.86 (22.76%)
293
What Year was the first public recommendation made by Geoffrey Porges?